{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:18:32Z","timestamp":1782983912950,"version":"3.54.5"},"reference-count":65,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Hypertrophic Cardiomyopathy (HCM) is one of the most common inherited cardiomyopathies and remains an important cause of ventricular arrhythmias and sudden cardiac death (SCD), particularly in younger individuals. Although the annual incidence of arrhythmic death is relatively low in contemporary cohorts, identifying those patients who may benefit from primary prevention with an implantable cardioverter-defibrillator (ICD) remains a major clinical challenge. Current risk stratification strategies rely on two principal paradigms. The European approach is centered on the HCM Risk-SCD score, whereas the American approach is mainly based on major clinical risk markers. Both strategies have important strengths and limitations, reflecting the persistent difficulty of accurately predicting arrhythmic events in such a heterogeneous disease. The HCM Risk-SCD score has demonstrated robust external validation and high specificity for identifying patients at higher risk, but it may fail to recognize some vulnerable individuals who remain below conventional treatment thresholds. For this reason, several additional risk modifiers have gained increasing relevance in contemporary practice. Among them, extensive late gadolinium enhancement, left ventricular systolic dysfunction, apical aneurysm, and clinically meaningful genetic findings may provide important incremental prognostic information beyond traditional models. Emerging disease-modifying therapies, in particular Mavacamten, may also influence future risk assessment. However, whether these improvements translate into a true reduction in SCD risk remains uncertain. Importantly, the decision to implant an ICD should not depend on numerical risk alone. It should arise from a process of shared decision-making integrating estimated risk, treatment burden, competing comorbidities, age, lifestyle, and patient values. In this context, the concept of an individualized threshold of \u201cacceptable risk\u201d becomes central. In conclusion, prevention of SCD in HCM is moving beyond conventional scores toward a personalized and dynamic framework in which predictive tools, advanced phenotyping, evolving therapies, clinical expertise, and patient preferences are combined to guide individualized care.<\/jats:p>","DOI":"10.3390\/jpm16060287","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:02:51Z","timestamp":1779793371000},"page":"287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Personalized Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy: Beyond Conventional Risk Scores"],"prefix":"10.3390","volume":"16","author":[{"given":"Jacopo","family":"Costantino","sequence":"first","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00185 Roma, Italy"},{"name":"Department of Medicine, University of Padua, 35128 Padova, Italy"},{"name":"Department of Cardiology, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5061-0424","authenticated-orcid":false,"given":"Federico","family":"Ballatore","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Porcelli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Romani","sequence":"additional","affiliation":[{"name":"Department of Cardiology, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Campoli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Maria","family":"Zuccaro","sequence":"additional","affiliation":[{"name":"Department of Cardiology, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marchionni","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00185 Roma, Italy"},{"name":"Department of Medicine, University of Padua, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alfarano","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Costantino","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical Course and Management of Hypertrophic Cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.jacc.2016.08.079","article-title":"Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy","volume":"68","author":"Burke","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamacardio.2019.4534","article-title":"Mortality Among Referral Patients with Hypertrophic Cardiomyopathy vs the General European Population","volume":"5","author":"Lorenzini","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/europace\/euaa307","article-title":"Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: A UK National Cohort Study","volume":"23","author":"Norrish","year":"2021","journal-title":"Europace"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"Jichi","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced American College of Cardiology\/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients with Hypertrophic Cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_11","first-page":"15","article-title":"Validation of the New American College of Cardiology\/American Heart Association Guidelines for the Risk Stratification of Sudden Cardiac Death in a Large Mediterranean Cohort with Hypertrophic Cardiomyopathy","volume":"63","author":"Zegkos","year":"2022","journal-title":"Hell. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.amjcard.2017.10.027","article-title":"Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association\/American College of Cardiology Foundation Risk Stratification Systems for Patients with Hypertrophic Cardiomyopathy","volume":"121","author":"Leong","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1093\/eurheartj\/ehab598","article-title":"Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy","volume":"42","author":"Nauffal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/CIRCULATIONAHA.117.030437","article-title":"International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)","volume":"137","author":"Jichi","year":"2018","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/heartjnl-2018-313700","article-title":"Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: A systematic review and meta-analysis","volume":"105","author":"Akhtar","year":"2019","journal-title":"Heart"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2015.05.047","article-title":"Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy","volume":"116","author":"Maron","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijcard.2022.03.028","article-title":"Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis","volume":"357","author":"Mascia","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ijcard.2022.10.153","article-title":"Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management","volume":"370","author":"Brignole","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/pace.12861","article-title":"Rapid Device-Detected Nonsustained Ventricular Tachycardia in the Risk Stratification of Hypertrophic Cardiomyopathy","volume":"39","author":"Viswanathan","year":"2016","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","article-title":"Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy","volume":"342","author":"Spirito","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic Cardiomyopathy with Left Ventricular Apical Aneurysm: Implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.108.781401","article-title":"Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy","volume":"118","author":"Maron","year":"2008","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jjcc.2014.02.011","article-title":"Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: The role of diagnostic electrocardiography","volume":"64","author":"Ichida","year":"2014","journal-title":"J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/hrt.61.2.178","article-title":"Clinical Sustained Uniform Ventricular Tachycardia in Hypertrophic Cardiomyopathy: Association with Left Ventricular Apical Aneurysm","volume":"61","author":"Alfonso","year":"1989","journal-title":"Heart"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2021.03.056","article-title":"Prognostic Role of Left Ventricular Apical Aneurysm in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis","volume":"332","author":"Papanastasiou","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/eurheartj\/ehad122","article-title":"Do apical aneurysms predict sudden cardiac death in hypertrophic cardiomyopathy?","volume":"44","author":"Lorenzini","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pcad.2020.11.001","article-title":"Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis","volume":"66","author":"Kamp","year":"2021","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10554-020-01808-6","article-title":"Myocardial Tissue Characterization by Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging for Risk Stratification of Adverse Events in Hypertrophic Cardiomyopathy","volume":"36","author":"Raiker","year":"2020","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kariki, O., Antoniou, C.-K., Mavrogeni, S., and Gatzoulis, K.A. (2020). Updating the Risk Stratification for Sudden Cardiac Death in Cardiomyopathies: The Evolving Role of Cardiac Magnetic Resonance Imaging. An Approach for the Electrophysiologist. Diagnostics, 10.","DOI":"10.3390\/diagnostics10080541"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1532-429X-14-13","article-title":"Clinical Utility of Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy","volume":"14","author":"Maron","year":"2012","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jcmg.2010.11.015","article-title":"Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance","volume":"4","author":"Flett","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcmg.2023.07.005","article-title":"Quantitative Late Gadolinium Enhancement Cardiac Magnetic Resonance and Sudden Death in Hypertrophic Cardiomyopathy: A Meta-Analysis","volume":"17","author":"Kiaos","year":"2024","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jcmg.2020.09.037","article-title":"Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Cardiac Magnetic Resonance Study","volume":"14","author":"Habib","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jjcc.2015.07.020","article-title":"The Value of Cardiac Magnetic Resonance and Distribution of Late Gadolinium Enhancement for Risk Stratification of Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy","volume":"68","author":"Klopotowski","year":"2016","journal-title":"J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ehjci\/jev154","article-title":"Late Gadolinium Enhancement Confined to the Right Ventricular Insertion Points in Hypertrophic Cardiomyopathy: An Intermediate Stage Phenotype?","volume":"17","author":"Bravo","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in Patients with Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/ehf2.13914","article-title":"Hypokinetic Hypertrophic Cardiomyopathy: Clinical Phenotype, Genetics, and Prognosis","volume":"9","author":"Wasserstrum","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/heartjnl-2022-321853","article-title":"Prognosis of Patients with Hypertrophic Cardiomyopathy and Low-Normal Left Ventricular Ejection Fraction","volume":"109","author":"Choi","year":"2023","journal-title":"Heart"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjcard.2010.03.020","article-title":"Spectrum and Clinical Significance of Systolic Function and Myocardial Fibrosis Assessed by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy","volume":"106","author":"Olivotto","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/eurheartj\/ehp327","article-title":"Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy","volume":"30","author":"Gimeno","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0735-1097(00)01003-2","article-title":"Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients","volume":"36","author":"Elliott","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1161\/01.CIR.96.9.2987","article-title":"Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy","volume":"96","author":"Sadoul","year":"1997","journal-title":"Circulation"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1161\/01.CIR.82.6.1995","article-title":"Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy","volume":"82","author":"Frenneaux","year":"1990","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/01.CIR.84.2.686","article-title":"Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy","volume":"84","author":"Counihan","year":"1991","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijcard.2018.07.110","article-title":"Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death","volume":"274","author":"Smith","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/2047487317702519","article-title":"Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis","volume":"24","author":"Norrish","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.amjcard.2016.06.038","article-title":"Value of Genetic Testing for the Prediction of Long-Term Outcome in Patients with Hypertrophic Cardiomyopathy","volume":"118","author":"Vriesendorp","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/heartjnl-2014-307205","article-title":"Phenotype and prognostic correlations of the converter region mutations affecting the \u03b2 myosin heavy chain","volume":"101","author":"Arad","year":"2015","journal-title":"Heart"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/hc3701.095952","article-title":"Hypertrophic cardiomyopathy: Histopathological features of sudden death in cardiac troponin T disease","volume":"104","author":"Varnava","year":"2001","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s004390050695","article-title":"A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes","volume":"102","author":"Jeschke","year":"1998","journal-title":"Hum. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41588-025-02094-5","article-title":"Evaluation of Polygenic Scores for Hypertrophic Cardiomyopathy in the General Population and across Clinical Settings","volume":"57","author":"Zheng","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Alfarano, M., Ciccarelli, F., Marchionni, G., Ballatore, F., Costantino, J., Lattanzio, A., Pecci, G., Stavagna, S., Iannelli, L., and Galardo, G. (2025). Hypertrophic Cardiomyopathy and Phenocopies: New Therapies for Old Diseases-Current Evidence and Future Perspectives. J. Clin. Med., 14.","DOI":"10.3390\/jcm14124228"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients with Obstructive Hypertrophic Cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jcmg.2025.07.019","article-title":"Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated with Mavacamten for Up to 128 Weeks: Insights from the VALOR-HCM Trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"ytaf592","DOI":"10.1093\/ehjcr\/ytaf592","article-title":"Complete left bundle branch block resolution during treatment with Mavacamten: A case report of a first-in-class scenario","volume":"9","author":"Marchionni","year":"2025","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_65","first-page":"euaf085.717","article-title":"Effect of Mavacamten on reducing sudden cardiac death risk in patients with Obstructive Hypertrophic Cardiomyopathy: An evaluation using the HCM-SCD Risk Score","volume":"27","author":"Costantino","year":"2025","journal-title":"EP Eur."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/6\/287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:23:15Z","timestamp":1779794595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/6\/287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jpm16060287"],"URL":"https:\/\/doi.org\/10.3390\/jpm16060287","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}